Cellares and ProTgen announced a partnership to automate manufacturing and quality control for ProT-096, a personalized progenitor T-cell therapy aimed at refractory leukemia and other hematologic malignancies. The companies said Cellares will use its Cell Shuttle and Cell Q platforms, and will provide regulatory support toward an IND submission. The collaboration targets a major bottleneck for next-generation cell therapies: producing consistent, scalable manufactured products for personalized regimens. Cellares said its workflow reduces manual touchpoints and is designed to maintain GMP-grade quality across runs, equipment, and facilities. ProTgen’s approach relies on targeted Notch activation to rebuild adaptive immune repertoire by reactivating the thymus, with the program aimed at patients whose immune systems are compromised after intensive treatment. By bundling automated manufacturing with regulatory support, the partnership seeks to accelerate development without forcing early-stage teams to choose between clinical timelines and the infrastructure needed for larger trials.